236 related articles for article (PubMed ID: 34561376)
21. Morphology and Immunohistochemistry for 2SC and FH Aid in Detection of Fumarate Hydratase Gene Aberrations in Uterine Leiomyomas From Young Patients.
Joseph NM; Solomon DA; Frizzell N; Rabban JT; Zaloudek C; Garg K
Am J Surg Pathol; 2015 Nov; 39(11):1529-39. PubMed ID: 26457356
[TBL] [Abstract][Full Text] [Related]
22. Fumarate Hydratase-Deficient Leiomyoma of the Uterine Corpus: Comparative Morphologic Analysis of Protein-Deficient Tumors With and Without Pathogenic Germline Fumarate Hydratase Gene Mutations.
Shi W; Liu Y; Aisagbonhi O; Roma AA; Hasteh F; Zare SY; Fadare O
Int J Surg Pathol; 2024 Apr; 32(2):340-355. PubMed ID: 37312573
[TBL] [Abstract][Full Text] [Related]
23. [FH-deficient renal cell carcinoma expands the spectrum of renal papillary tumors].
Rupp N; Moch H
Pathologe; 2021 Nov; 42(6):560-564. PubMed ID: 34448900
[TBL] [Abstract][Full Text] [Related]
24. Immunoexpression of SDHB, FH, and CK20 among eosinophilic renal tumors: A tissue microarray study.
Karatay H; Ozluk Y; Dogan MA; Erdem S; Kilicaslan I
Ann Diagn Pathol; 2021 Oct; 54():151788. PubMed ID: 34246177
[TBL] [Abstract][Full Text] [Related]
25. Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.
Kwon R; Argani P; Epstein JI; Lombardo KA; Wang X; Pierorazio PM; Mehra R; Matoso A
Am J Surg Pathol; 2021 Apr; 45(4):450-462. PubMed ID: 33239504
[TBL] [Abstract][Full Text] [Related]
26. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach.
Wyvekens N; Valtcheva N; Mischo A; Helmchen B; Hermanns T; Choschzick M; Hötker AM; Rauch A; Mühleisen B; Akhoundova D; Weber A; Moch H; Rupp NJ
Genes Chromosomes Cancer; 2020 Nov; 59(11):611-619. PubMed ID: 32537760
[TBL] [Abstract][Full Text] [Related]
27. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
[TBL] [Abstract][Full Text] [Related]
28. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature.
Hol JA; Jongmans MCJ; Littooij AS; de Krijger RR; Kuiper RP; van Harssel JJT; Mensenkamp A; Simons M; Tytgat GAM; van den Heuvel-Eibrink MM; van Grotel M
Fam Cancer; 2020 Jan; 19(1):55-63. PubMed ID: 31792767
[TBL] [Abstract][Full Text] [Related]
29. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
[TBL] [Abstract][Full Text] [Related]
30. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
[No Abstract] [Full Text] [Related]
31. Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinoma.
Mannan R; Wang X; Bawa PS; Chugh S; Chinnaiyan AK; Rangaswamy R; Zhang Y; Cao X; Smith SC; Trpkov K; Williamson SR; Sangoi AR; Mohanty S; McKenney JK; Gupta S; Magi-Galluzzi C; Argani P; Osunkoya AO; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Hum Pathol; 2023 Apr; 134():102-113. PubMed ID: 36581128
[TBL] [Abstract][Full Text] [Related]
32. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
[TBL] [Abstract][Full Text] [Related]
33. Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.
Sanz-Ortega J; Vocke C; Stratton P; Linehan WM; Merino MJ
Am J Surg Pathol; 2013 Jan; 37(1):74-80. PubMed ID: 23211287
[TBL] [Abstract][Full Text] [Related]
34. [FH (Fumarate Hydratase)-deficient renal cell carcinoma: A case report].
Allaume P; Kammerer-Jacquet SF; Papadopoulos S; Rioux-Leclercq N
Ann Pathol; 2023 Sep; 43(5):417-420. PubMed ID: 36822902
[TBL] [Abstract][Full Text] [Related]
35. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
36. Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients.
Li Y; Reuter VE; Matoso A; Netto GJ; Epstein JI; Argani P
Histopathology; 2018 Mar; 72(4):588-600. PubMed ID: 28898443
[TBL] [Abstract][Full Text] [Related]
37. GATA3 aids in distinguishing fumarate hydratase-deficient renal cell carcinoma from papillary renal cell carcinoma.
Liu Y; Dong Y; Gu Y; Xu H; Fan Y; Li X; Dong L; Zhou L; Yang X; Wang C
Ann Diagn Pathol; 2022 Oct; 60():152007. PubMed ID: 35841867
[TBL] [Abstract][Full Text] [Related]
38. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
[TBL] [Abstract][Full Text] [Related]
40. Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma.
Kiyozawa D; Kohashi K; Takamatsu D; Iwasaki T; Shibata D; Tomonaga T; Tateishi Y; Eto M; Kinjo M; Nishiyama K; Taguchi K; Oshiro Y; Kuboyama Y; Furuya M; Oda Y
Hum Pathol; 2022 Jun; 124():36-44. PubMed ID: 35306021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]